Literature DB >> 25549047

Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.

Cecilia Karlsson1, Stephan Hjorth, Martin Karpefors, Göran I Hansson, Björn Carlsson.   

Abstract

The individual weight loss response to obesity treatment is diverse. Here we test the hypothesis that the weight loss response to the CB1 receptor antagonist rimonabant is influenced by endogenous levels of receptor agonists. We show that baseline anandamide levels and body weight independently contribute to predict the treatment response to rimonabant in rodents, demonstrating that addition of biomarkers related to mode of action is relevant for a personalized health care approach to obesity treatment.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25549047      PMCID： PMC4399312          DOI： 10.1210/en.2014-1730

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


  16 in total

1.  The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.

Authors:  Zoë D Thornton-Jones; Guy A Kennett; Karen R Benwell; Dean F Revell; Anil Misra; Daniel M Sellwood; Steven P Vickers; Peter G Clifton
Journal:  Pharmacol Biochem Behav       Date:  2006-06-30       Impact factor: 3.533

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

4.  Release of anandamide from blood cells.

Authors:  Michael Vogeser; Daniela Hauer; Shahnaz Christina Azad; Erasmus Huber; Martin Storr; Gustav Schelling
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

5.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

6.  Predictors of weight loss in adults with topiramate-treated epilepsy.

Authors:  Elinor Ben-Menachem; Mette Axelsen; Else Hellebö Johanson; Anna Stagge; Ulf Smith
Journal:  Obes Res       Date:  2003-04

7.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

Authors:  R Mechoulam; S Ben-Shabat; L Hanus; M Ligumsky; N E Kaminski; A R Schatz; A Gopher; S Almog; B R Martin; D R Compton
Journal:  Biochem Pharmacol       Date:  1995-06-29       Impact factor: 5.858

8.  Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Authors:  Luc Van Gaal; Xavier Pi-Sunyer; Jean-Pierre Després; Christine McCarthy; André Scheen
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

Review 9.  The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders.

Authors:  Cristoforo Silvestri; Vincenzo Di Marzo
Journal:  Cell Metab       Date:  2013-04-02       Impact factor: 27.287

10.  Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

Authors:  S P Vickers; L J Webster; A Wyatt; C T Dourish; G A Kennett
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530
View more
  1 in total

Review 1.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.